REDER ROBERT F.,GOLDENHEIM PAUL D.,KAIKO ROBERT F.
申请号：
SI9830937
公开号：
SI2305194T1
申请日:
1998.02.24
申请国别(地区):
SI
年份:
2012
代理人:
摘要：
A sustained release formulation of buprenorphine is new. The composition comprises a transdermal delivery device which provides a first order release of buprenorphine over a 3-day dosing interval so that a maximum plasma concentration of 20 10 1052 pg/ml is obtained. the device then provides zero order kinetics over at least 2 more days.
